semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer stage 1: 1. female 2. ≥18 years old 3. invasive ductal carcinoma or DCIS proved by core needle biopsy 4. tumor size ≤ 5cm 5. negative preoperative axillary assessment(including body examination, ultrasound and MR examination) 6. patients is accessible for the following axillary surgery and pathological test(including sentinel lymph node biopsy and axillary lymph node dissection) stage 2: 1. female 2. ≥18 years old 3. invasive carcinoma proved by core needle biopsy 4. has plan for breast conserving surgery and adjuvant radiation after surgery 5. negative preoperative axillary assessment(including body examination, ultrasound and axillary PET mSUV<0.27) 6. patients is accessible for the follow up  stage 1: 1. distant metastases 2. in the procedure of neoadjuvant therapy 3. positive preoperative axillary assessment (including body examination, ultrasound and MR examination) 4. pregnancy or breastfeeding 5. axillary biopsy or axillary surgery before LymphPET 6. suffer from diabetes mellitus and without well control of bloodglucose 7. previous malignancy 8. allergic to tracer of LymphPET stage 2: 1. distant metastases 2. in the procedure of neoadjuvant therapy 3. positive preoperative axillary assessment (including body examination, ultrasound and PET mSUV≥0.27) 4. pregnancy or breastfeeding 5. axillary biopsy or axillary surgery before LymphPET 6. suffer from diabetes mellitus and without well control of bloodglucose 7. previous malignancy 8. allergic to tracer of LymphPET
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Pain, Postoperative Patients scheduled for elective craniotomy for resection of tumour under general anaesthesia American Society of Anesthesiologists (ASA) physical status of I , II or III Participates with an anticipated fully recovery within 2 hours postoperatively  History of craniotomy Expected delayed extubation or no plan to extubate Participants who cannot use a patient-controlled analgesia (PCA) device • Participants who cannot understand the instructions of a numeral rating scale (NRS) 35 before surgery Extreme body mass index (BMI) (< 15 or > 35) Allergy to opioids, methylprednisolone or ropivacaine History of excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks), or use of drugs with confirmed or suspected sedative or analgesic effects History of psychiatric disorders, uncontrolled epilepsy or chronic headache Pregnant or at breastfeeding Symptomatic cardiopulmonary, renal, or liver dysfunction or history of diabetes
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Neoplastic Disease Solid Tumor Patients with a primary or relapsed solid tumor or lymphoma who require excision of the tumor or metastatic lesions  Subjects with a history of iodide allergies, including positive allergic reaction to the screening iodine test Inability or unwillingness of research participant or legal guardian/representative to give written informed consent Patients with benign pathology Patients with brain tumors Pregnant female
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Cervical cancer histopathological diagnosis Clinical stage IB1 or IIA1 CC Treated with radical hysterectomy (RH) with bilateral pelvic lymphadenectomy (BPL)  Double primary tumors Treatment regimens other than standard treatment Poor quality formalin-fixed paraffin-embedded tissue blocks
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female Breast Cancer Written informed consent prior to breast-conserving surgery, including expected cooperation of the patients for follow-up, must be obtained and documented according to the European regulatory requirements Histologically confirmed unilateral primary invasive carcinoma of the breast (core biopsy). Multifocal or multicentric tumors are allowed if breast-conserving surgery is planned Age at diagnosis at least 18 years imaging techniques with estimated tumor stage between cT1c-T3 prior to NAST triple-negative or HER2-positive invasive breast cancer clinically and sonographically tumor-free axilla prior to core biopsy (cN0/iN0) in cases with cN0 and iN+, a negative core biopsy or fine needle aspiration (FNA) biopsy of the sonographically suspected lymph node is required no evidence for distant metastasis (M0) standard NAST with radiologic complete response (rCR) planned breast-conserving surgery with postoperative external whole-breast irradiation (conventional fractionation or hypofractionation)  History of malignancy within last 5 years, except curatively treated basalioma of the skin and carcinoma in situ of the cervix Time since last cycle of NAST >3 months (optimal <1 month) histologically non-invasive breast carcinoma ER-positive/HER2-negative disease (triple-positive tumors are allowed) cT4 or iT4 tumors pregnant or lactating patients no radiologic complete response at the end of NAST planned total mastectomy after NAST planned intraoperative radiotherapy (e.g. Intrabeam) or postoperative partial breast irradiation (e.g. multicatheter technique) alone; both procedures are allowed as boost techniques male patients
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Sentinel Lymph Node Neoplasm, Breast T1-3N1M0 breast cancer at diagnosis (prior to NACT) by American Joint Committee on Cancer (AJCC) staging 7th edition Fine-needle aspiration (FNA) or core biopsy confirmed axillary nodal metastases at presentation Oestrogen receptor, progesterone receptor and HER2 status evaluated on primary tumour Received standard NACT as per local guidelines Ultrasound of the axilla at completion of NACT Undergo dual tracer sentinel node biopsy after NACT and at least 3 nodes removed (sentinel nodes and marked node). If axillary node sampling is performed following failed localisation of sentinel nodes, patient will be eligible if at least 3 nodes removed (including the marked node) No nodal metastases post NACT (isolated tumour cells, micro or macrometastasis)  Bilateral invasive breast cancer Sentinel node biopsy prior to NACT Marked node not removed except where the node/s removed show evidence of downstaging with complete pathological response e.g. fibrosis or scarring Previous axillary surgery on the same body side as the scheduled targeted sampling Radiation therapy for the currently diagnosed breast cancer prior to randomisation Previous cancer within 5 years or concomitant malignancy except basal or squamous cell carcinoma of the skin in situ carcinoma of the cervix in situ melanoma
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed primary breast cancer No prior chemotherapy Eligible for Oncotype DX ® testing as per current Ontario funding including: ER positive, PR positive or negative, HER2 negative, lymph node status negative or micro-invasive disease, tumor >1 cm in size (or if equal or <1 cm, must be grade 2/3 or have lymph node micrometastasis)  Neoadjuvant treatment including window of opportunity trials Recurrent breast cancer
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Breast Cancer Female ≥ 18 years of age pre and post-menopausal Oligometastatic disease (≤ 5 sites of disease) Premenopausal status is defined as either Patient had last menstrual period within the last 12 months, OR If on tamoxifen or toremifene within the past 14 days, plasma estradiol and FSH must be in the premenopausal range per local normal range, OR In case of therapy induced amenorrhea, plasma estradiol and/or FSH must be in the premenopausal range per local normal range Patients who have undergone bilateral oophorectomy are eligible Post-menopausal status defined as either 1) at least 2 years without menstrual period or 2) patients older than 50 with serological evidence of post-menopausal status or 3) hysterectomized patients of any age with FSH confirmation of post-menopausal status Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Biopsy proven diagnosis of HR+HER2  Active connective tissue disorders, such as lupus or scleroderma requiring flare therapy Current use of systemic chemotherapy, endocrine therapy or HER2-neu targeted therapy Male breast cancer patients Any lesion >5 cm in greatest diameter Inability to obtain histologic proof of metastatic breast cancer Has received previous endocrine or chemotherapy for metastatic breast cancer Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug Has a known additional malignancy (second primary) that is progressing or has required active treatment within the past 3 years. Note Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. cervical cancer in situ) that have undergone potentially curative therapy are not excluded Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Triple Negative Breast Cancer HER2-positive Breast Cancer Sentinel Lymph Node Women, aged ≥ 18 years Invasive HER2+ (HR+/-) or TN breast cancer Primary tumor (T), clinical stage T1-3 Neoadjuvant systemic therapy (NST), at least 3 cycles Tumor stage assessed with breast MRI before start NST Clinically node-negative before start NST (no suspect ALNs on ultrasound and FGD-PET/CT, or negative cyto-/histopathology in case of suspect nodes) MRI after or during NST shows radiologic complete response Written and signed informed consent  Primary tumor (T) clinical stage T4 Patients without ultrasound or FDG-PET/CT pre-NST History of breast cancer ipsilateral breast Synchronous contralateral breast cancer Synchronous M1 disease
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female Female Age 18 years or older Invasive ductal breast carcinoma and ductal carcinoma in situ having undergone breast conservation surgery May neo-adjuvant treated subjects (chemotherapeutic, endocrine therapy, or radiation) Ability to understand and the willingness to sign a written informed consent document  Metastatic cancer (Stage IV) Lobular carcinoma as primary diagnosis
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  DCIS Invasive Breast Cancer Breast cancer patients with DCIS or invasive breast cancer Undergoing breast conserving surgery and adjuvant radiation Subjects must be willing and able to provide breast skin samples  Active clinical breast infection (on antiobiotic for skin/breast infection or clinical diagnosis) Refuse or are unable to sign informed consent form Past history of breast cancer
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Breast Cancer Women with histological confirmed ER/PR positive, HER2-negative MBC Age >18 years old Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC Adequate hematologic, renal and hepatic function Signed informed consent (ICF)  Active malignancy other than MBC Active infection
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Invasive Lobular Breast Carcinoma Adults aged 18 years or greater All patients or legal guardians are willing and able to sign a written informed consent and HIPAA authorization in accordance with local and institutional guidelines Histologically confirmed invasive lobular carcinoma within the past 12 weeks confirmed from biopsy of primary tumor or metastasis Patient is willing to have their clinical records reviewed for at least 24 months after enrollment  Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. Patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion Patients who require monitored anesthesia for PET/CT scanning Patients who are too claustrophobic to undergo PET/CT scanning Pregnancy or current breast feeding Any patient that is medically unstable defined as patient requiring inpatient hospitalization or needing evaluation at an acute care or urgent care facility at time of imaging Patients undergoing treatment with estrogen receptor agonists (such as fulvestrant and tamoxifen) within 5 weeks of the FES-PET/CT scan. (Note that aromatase inhibitors and luteinizing hormone-releasing hormone agonists do not affect ER expression, or binding of FES to ER, and do not need to be discontinued or considered for or of patients) Patient who have had the site(s) of biopsy proven invasive lobular carcinoma surgically resected
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.5-1.0,  Ovarian Neoplasms Ovarian germ cell tumors : 1. benign ( mature cystic teratoma ). 2. malignant ones ( dysgerminoma , immature teratoma and yolk sac tumor)  Epithelial ovarian tumors 2. sex cord -stromal ovarian tumors. 3. metastatic ovarian lesions